But the $1B in revenue won’t belong to PYC unless it funds the Phase 2/3 itself, and it doesn’t have the funds to do that IMO. Therefore, the most likely way forward is to license the drug out to (at least some) countries.
At least that funding is non-dilutive.
PYC Price at posting:
6.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)